# Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients.

> **NCT04471441** · PHASE4 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 150 (actual)

## Conditions studied

- Liver Transplant

## Interventions

- **DRUG:** Everolimus Tab.
- **DRUG:** Mycophenolate mofetil Tab./Cap.

## Key facts

- **NCT ID:** NCT04471441
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-30
- **Primary completion:** 2024-07-24
- **Final completion:** 2024-07-24
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04471441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04471441, "Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04471441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*